Abstract
Objective
To evaluate the influence of pentoxifylline (PTX), a phosphodiesterase inhibitor, on cytokines and inflammatory proteins in patients suffering from septic shock.
Design
Prospective study comparing a therapy group to a matched control group.
Setting
Medical intensive care unit at a university hospital.
Patients
Twenty four patients fulfilling the criteria of septic shock were included in this study. Twelve patients received PTX (therapy group) and 12 patients matched for diagnosis, age and gender served as the control group.
Interventions
Pentoxifylline at 1 mg/kg per hour over 24 h in the therapy group.
Measurements ad results
Cytokine levels [tumor necrosis factor-α (TNF)], soluble TNF receptor [TNF-R], and interleukin-6 [IL-6] and inflammatory proteins [C-reactive protein, α-1-antitrypsin (AAT), fibronectin, and haptoglobin], as well as hemodynamic parameters and the APACHE III score were evaluated before initiation of therapy and 24 h later. After 24 h, TNF levels were significantly lower in the therapy group (p=0.013), while IL-6 levels were significantly higher in the therapy group (p=0.030). Within the 24 h TNF declined significantly in the therapy group (p=0.006), while IL-6 showed a significant increase (p=0.043). AAT and the APACHE III score tended to differ significantly after 24 h between the groups [AAT levels higher in the therapy group (p=0.05), APACHE III score lower (p=0.05)]. In the therapy group, the systemic vascular resistance index was significantly higher after 24 h (p=0.0026) whereas the cardiac index declined (p=0.035).
Conclusions
PTX does influence TNF levels in septic shock patients. Nevertheless, inhibiting a single mediator in severe septic shock cannot stop the inflammatory overreaction.
Similar content being viewed by others
References
Moldawer LL (1994) Biology of proinflammatory cytokines and their antagonists. Crit Care Med 22:S 3-S 7
Bone RC (1994) Sepsis and its complications: the clinical problem. Crit Care Med 22:S 8-S 11
Bellomo R (1992) The cytokine network in the critically ill. Anaesth Intensive Care 20:288–302
Parrillo JE (1993) Pathogenetic mechanisms of septic shock. N Engl J Med 328:1471–1477
Suffredini AF (1994) Current prospects for the treatment of clinical sepsis. Crit Care Med 22:S 12-S 18
Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA (1991) Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110:192–198
Beutler B, Grau GE (1993) Tumor necrosis factor in the pathogenesis of infectious disease. Crit Care Med 21:S423-S435
Mackay J, Boyd OF, Henderson S, Bennett ED (1992) Pentoxifylline causes a dose dependent reduction in mortality in patients with sepsis syndrome (abstract). Clin Sci 82:33P
Mayer N, Steltzer H, Klimscha W, Oismueller C, Hammerle AF (1991) Cardiorespiratory effects of pentoxifylline in septic and non-septic states (abstract). Anesthesiology 75:A232
Harada H, Ishizaka A, Yonemaru M, Mallick AA, Hatherill JR, Zheng H (1989) The effects of aminophylline and pentoxifylline on multiple organ damage afterEscherichia coli sepsis. Am Rev Respir Dis 140:974–980
Noel P, Nelson S, Bokulic R, Bagby G, Lippton H, Lipscomb G (1990) Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and positively influences mortality. Life Sci 47:1023–1029
Schade UF (1990) Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ Shock 31: 171–181
Barraso-Aranda J, Schmit-Schoenbein GW (1990) Pentoxifylline pretreatment decreases neutrophil activation during endotoxin shock and improves survival. In: Hakim J, Mandell GL, Novick WJ (ed) Pentoxifylline and analogues: effects on leukocyte function. Karger, Basel, pp 86–90
Law WR, Nadkarni VM, Fletcher MA, Nevola JJ, Eckstein JM, Quance J (1992) Pentoxifylline treatment of sepsis in conscious Yucatan minipigs. Circ Shock 37:291–300
Sarma PSA (1990) Pentoxifylline in septic shock. Postgrad Med J 66: 980–981
Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA (1989) Sepsis syndrome: a valid clinical entity. Crit Care Med 17:389–393
Sullivan GW, Carper HT, Novick WJ, Mandell GL (1988) Pentoxifylline inhibits the inflammatory effects of endotoxin and endotoxin-induced cytokines on neutrophil function. In: Mandell GL, Novick WJ (eds) Pentoxifylline and leukocyte function. Hoechst-Roussel, Sommerville, pp 37–48
Rao KMK, Padmanabhan J, Cohen HJ, Curris MS (1990) Effect of pentoxifylline and analogs on actin state and cell surface receptor expression in human leukocytes. In: Hakim J, Mandell GL, Novick WJ (eds) Pentoxifylline and analogues: effects on leukocyte function. Karger, Basel, pp 64–70
Barroso-Aranda J, Schmid-Schoenbein GW (1990) Pentoxifylline pretreatment decrease the pool of activated neutrophils, in-vivo adhesion to endothelium, and improves survival from hemorrhagic shock. Biorheology 27:401–418
Sourbier P, Perianin A, Hakim J (1988) In vitro effects of pentoxifylline on human neutrophil function. In: Mandell GL, Novick WJ (eds) Pentoxifylline and leukocyte function. Hoechst-Roussel-Sommerville, pp 56–67
Slater K, Wiseman MS, Shale DJ, Fletcher J (1988) The effect of pentoxifylline on neutrophil function in vitro and ex vivo in human volunteers. In: Mandell GL, Novick WJ (eds) Pentoxifylline and leukocyte function. Hochest-Roussel, Sommerville, pp 115–123
Kumar KV, Das UN, Kumar GS, Das NP, Tan BK (1992) Effect of pentoxifylline on freed radical generation in human peripheral leukocytes. Asia Pac J Pharmacol 7:89–93
Beutler B (1990) Cachectin/tumor necrosis factor and lymphotoxin. In: Sporn MB, Roberts AB (eds) Handbook of experimental pharmacology: peptide growth factors and their receptors II. Springer, Berlin Heidelberg New York, pp 39–70
Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ, Zentella A, Albert JD (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234:470–474
Tracey KJ, Lowry SF, Fahey TJ, Albert JD, Fong Y, Hesse D, Beutler B, Manogue KR, Calvano S, Wei H (1987) Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet 164:415–442
Tighe D, Moss R, Heath MF, Hynd J, Bennet ED (1989) Pentoxifylline reduces pulmonary leucostasis and improves capillary patency in a rabbit peritonitis model. Circ Shock 28:159–164
Tighe D, Moss R, Hynd J, Boghossian S, Al Saady N, Heath MF (1990) Pretreatment with pentoxifylline improves the hemodynamic and histologic changes and decreases neutrophil adhesiveness in a pig fecal peritonitis model. Crit Care Med 18:184–189
Zabel P, Wolter DT, Schoenharting MM, Schade UF (1989) Oxpentifylline in endotoxaemia. Lancet 334: 1474–1477
Beutler BA, Milsark IW, Cerami A (1985) Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol 135: 3972–3977
Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E (1993) Serum cytokine levels in human septic shock. Chest 103:565–575
Pfizenmaier K, Himmler A, Schutze S (1993) TNF receptors and TNF signal transduction. In: Beutler B (ed) Tumor necrosis factors: the molecules and their emerging roles in medicine. Raven, New York, pp 439–472
Higuch M, Aggarwal BB (1992) Inhibition of ligand binding and antiproliferative effects of tumor necrosis factor and lymphotoxin by soluble forms of recombinant P 60 and P 80 receptors. Biochem Biophys Res Commun 182: 638–643
Spinas GA, Keller U, Brockhaus M (1992) Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 90: 533–536
Porteu F, Nathan C (1990) Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 172:599–607
Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D (1992) Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323–329
Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutics agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151: 1548–1561
De Boer JP, Wolbink GJ, Thijs LG, Baars JW, Wagstaff J, Hack CE (1992) Interplay of complement and cytokines in the pathogenesis of septic shock. Immunopharmacology 24:135–148
Waage A, Sorensen M, Fladvad Stordal B (1990) Effects of pentoxifylline and HWA 138 on production of tumor necrosis factor and interleukin 6 from monocytes. In: Hakim J, Mandell GL, Novick WJ (eds) Pentoxifylline and analogues: effects on leukocyte function. Karger, Basel, pp 86–90
Zabel P, Schoenharting MM, Schade UF, Schlaak M (1991) Effects of pentoxifylline in endotoxinemia in human volunteers. Prog Clin Biol Res 367: 207–213
Schade UF (1989) The role of prostacyclin in the protective effects of pentoxifylline and other xanthine derivatives in endotoxin action in mice. Eicosanoids 2:183–188
Sinzinger H (1983) Pentoxifylline enhances formation of prostacyclin from rat vascular and renal tissue. Prostaglandin Leukocyte Med 12:217–226
Lefer AM, Lefer DJ (1993) Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock. Annu Rev Pharmacol Toxicol 33:71–90
Kainoh M, Imai R, Umetsu T, Hattori M, Nishio S (1990) Prostacyclin and beraprost sodium as suppressors of activated rat polymorphonuclear leukocytes. Biochem Pharmacol 39:477–484
Simpson PJ, Mitsos SE, Ventura A, Gallagher KP, Fantone JC, Abrams GD, Schork MA, Lucchesi BR (1987) Prostacyclin protects ischemic reperfused myocardium in the dog by inhibition of neutrophil activation. Am Heart J 113:129–137
Zabel P, Schade U (1993) Therapiestrategien gegen Mediatoren beim septischen Schock. Immun Infekt 21: 45–50
Roberts PJ, Yong KL, Khawa A, Johnson BV, Pizzey AR, Carver JE, Addison IE, Linch DC (1993) Pentoxyifylline at clinically achievable levels inhibits FMLP-induced neutrophil responses, but not priming, uregulation of cell-adhesion molecules, or migration induced by GM-CSF. Eur J Hematol 50:1–10
Endres S, Fülle HJ, Sinha B, Stoll D, Dinarello CA, Gerzer R, Weber PC (1991) Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-α and interleukin-1β by human mononuclear cells Immunology 72:56–60
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Staudinger, T., Presterl, E., Graninger, W. et al. Influence of pentoxifylline on cytokine levels and inflammatory parameters in septic shock. Intensive Care Med 22, 888–893 (1996). https://doi.org/10.1007/BF02044112
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02044112